Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Zendy

Stephen J. Schuster | Zendy; Michael Bishop | Zendy; Constantine S. Tam | Zendy; Edmund K. Waller | Zendy; Peter Borchmann | Zendy; Joseph P. McGuirk | Zendy; Ulrich Jäger | Zendy; Samantha Jaglowski | Zendy; Charalambos Andreadis | Zendy; Jason R. Westin | Zendy; Isabelle Fleury | Zendy; Veronika Bachanová | Zendy; S.R. Foley | Zendy; P. Joy Ho | Zendy; Stephan Mielke | Zendy; John Magenau | Zendy; Harald Holte | Zendy; Serafino Pantano | Zendy; Lida Pacaud | Zendy; Rakesh Awasthi | Zendy; Jufen Chu | Zendy; Özlem Anak | Zendy; Gilles Salles | Zendy; Richard T. Maziarz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author(s) -

Stephen J. Schuster,

Michael Bishop,

Constantine S. Tam,

Edmund K. Waller,

Peter Borchmann,

Joseph P. McGuirk,

Ulrich Jäger,

Samantha Jaglowski,

Charalambos Andreadis,

Jason R. Westin,

Isabelle Fleury,

Veronika Bachanová,

S.R. Foley,

P. Joy Ho,

Stephan Mielke,

John Magenau,

Harald Holte,

Serafino Pantano,

Lida Pacaud,

Rakesh Awasthi,

Jufen Chu,

Özlem Anak,

Gilles Salles,

Richard T. Maziarz

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1804980

Subject(s) - medicine , cytokine release syndrome , neutropenia , hematopoietic stem cell transplantation , diffuse large b cell lymphoma , lymphoma , refractory (planetary science) , transplantation , gastroenterology , febrile neutropenia , rituximab , clinical endpoint , oncology , phases of clinical research , salvage therapy , immunology , immunotherapy , chimeric antigen receptor , chemotherapy , clinical trial , cancer , physics , astrobiology

Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research